证券代码：301185 证券简称：鸥玛软件 公告编号：2025-027 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 项目名称：教育部教育考试院全国大学四、六级考试（CET）项目答题卡扫 描及网上评卷技术服务项目 招标编号：TC2503096/02 中标金额：1.00元人民币/考生 预算金额：人民币650万元/年，人民币1950万元/3年 采购人：教育部教育考试院 中标项目全国大学英语四、六级考试（以下简称为"CET"）每年全年报考 人次约为2600万（答题卡扫描及网上评卷技术服务）。此项目包2每年承担约为 年下半年CET共6次考试的答题卡扫描和网上评卷提供相关技术服务。项目中标 价格为1950万元，占公司2024年度经审计营业收入的9.18%。 中标项目为公司的主营业务，若能够签署正式项目合同并顺利实施，将对 公司业务发展及经营业绩产生积极影响。本项目对公司的业务独立性不构成影 响，公司主要业务不会因履行合同而对合同方形成依赖。 公司本次中标项目尚未与相关单位签订正式合同，中标项目的实施进度等 具体内容以最终签署的合同为准。敬请广大投资者谨慎决策，注意投资 ...

证券简称：美丽生态 证券代码：000010 公告编号：2025-035 深圳美丽生态股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳美丽生态股份有限公司（以下简称"公司"）第十一届董事会任期已届 满，根据《公司法》《深圳证券交易所股票上市规则》等法律法规、规范性文件 及《公司章程》的有关规定，公司于 2025 年 6 月 5 日召开第十一届董事会第二 十三次会议，审议通过了《关于选举公司第十二届董事会董事候选人的议案》和 《关于选举公司第十二届董事会独立董事候选人的议案》，现将具体情况公告如 下： 一、董事会换届选举情况 公司第十二届董事会由 5 名董事组成，其中独立董事 2 名。经公司第十一届 董事会第二十三次会议审议，董事会同意选举陈飞霖先生、张景春先生、陈美玲 女士为公司第十二届董事会董事候选人，选举吴树满先生、侯卫和先生为公司第 十二届董事会独立董事候选人，上述董事候选人简历附后。 独立董事候选人吴树满先生、侯卫和先生已取得独立董事资格证书，独立董 事候选人中，侯卫和先生为会计专业人士。 本次换届完成后，董事郑财先生不再担任公司董事， ...

证券代码：002823 证券简称：凯中精密 公告编号：2025-022 深圳市凯中精密技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏。 一、审议并通过《关于设立2025年员工持股计划管理委员会的议案》 为保证公司员工持股计划的顺利实施，保障持有人的合法权益，根据《深圳 市凯中精密技术股份有限公司2025年员工持股计划管理办法》（以下简称"《管 理办法》"）的有关规定，持有人会议同意设立2025年员工持股计划管理委员会， 作为2025年员工持股计划的日常管理和监督机构，代表持有人行使股东权利。员 工持股计划管理委员会由3名委员组成，设管理委员会主任1人，管理委员会委员 的任期为2025年员工持股计划的存续期。 表决结果：同意17,358,623份，占出席持有人会议的持有人所持份额总数的 出席持有人会议的持有人所持份额总数的0%。 二、审议并通过《关于选举2025年员工持股计划管理委员会委员的议案》 根据《管理办法》的有关规定，经本次持有人会议审议，同意选举伏艳、龚 晓华、周琼为2025年员工持股计划管理委员会委员，任期与公司2025年员工持股 ...

证券代码：002922 证券简称：伊戈尔 公 告编号：2025-053 伊戈尔电气股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 伊戈尔电气股份有限公司（以下简称"公司"）于近日接到控股股东佛山市 麦格斯投资有限公司（以下简称"麦格斯"）的通知，获悉其持有公司的部分股 份办理了解除质押及质押展期业务，具体事项如下： 一、 基本情况 （一）本次解除质押情况 是否为控股 | | | 本次解除质 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | | | | 占其所持股 | | 占公司总股 | | | | | | | 押数量 | | | | | | 质押起始 | | | | 日 | 解除日期 | | 质权人 | | | | | | | | | 名称 | 大股东及其 | | | | 份比例 | | 本比例 | | | | | | 一致行动人 | （股） | | | | | | | | | | 麦格斯 | 是 ...

Core Viewpoint - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, which is not expected to constitute a major asset restructuring or a restructuring listing [1][2] Group 1 - The transaction's audit and evaluation work is not yet completed, and the valuation and transaction price of the target assets have not been determined [1] - Based on preliminary calculations using financial data from both the listed company and the target company, the transaction is expected not to meet the standards for major asset restructuring as defined by the relevant regulations [1] - The company will provide a detailed analysis and disclosure regarding the determination of whether the transaction constitutes a major asset restructuring in the restructuring report [1] Group 2 - The controlling shareholder and actual controller of the listed company will remain Yuan Yuyu before and after the transaction [2] - There has been no change in control of the listed company in the past 36 months, and this transaction will not lead to a change in control, thus not constituting a restructuring listing as per the regulations [2]

Core Viewpoint - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, along with raising supporting funds, which constitutes a related party transaction [1] Group 1: Confidentiality Measures - The company has established an insider information management system to regulate insider information management as approved in the board meeting on August 11, 2022 [1] - The company has signed confidentiality agreements with the transaction counterparties to ensure strict confidentiality regarding the transaction details, disclosing information only as required by law or necessary for the transaction [1] - The company has implemented a registration management system for insider information personnel, limiting the knowledge scope of sensitive information related to the transaction [2] Group 2: Insider Information Management - The company has created an "Insider Information Personnel Registration Form" and a "Transaction Progress Memorandum," and has reported the list of insider information personnel to the Shenzhen Stock Exchange [2] - The company has conducted multiple reminders to insider information personnel about their confidentiality obligations and responsibilities, prohibiting them from disclosing information or trading based on insider information before legal disclosure [2] - The company has taken necessary and sufficient confidentiality measures, established a strict confidentiality system, and signed confidentiality clauses with transaction counterparties, ensuring compliance with confidentiality obligations prior to legal disclosure of the transaction information [2]

深圳美丽生态股份有限公司 上市公司独立董事提名人声明与承诺 提名人深圳美丽生态股份有限公司董事会现就提名侯卫和为深圳美丽生态 股份有限公司第十二届董事会独立董事候选人发表公开声明。被提名人侯卫和 已书面同意作为深圳美丽生态股份有限公司（以下简称"美丽生态"或者"公司"） 第十二届董事会独立董事候选人(参见该独立董事候选人声明)。本次提名是在 充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、有无重大 失信等不良记录等情况后作出的，本提名人认为被提名人符合相关法律、行政 法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任 职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过美丽生态第十一届董事会提名委员会或者独立董事 专门会议资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立 履职情形的密切关系。 ?是□否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不 得担任公司董事的情形。 ?是□否 五、被提名人已经参加培训并取得证券交易所认可的相关培训证明材料(如 有)。 ...

Core Viewpoint - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. is planning a major asset restructuring involving the acquisition of 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of share issuance and cash payment, along with fundraising for related transactions [2]. Shareholding Situation - As of May 21, 2025, the top ten shareholders of the company hold only ordinary shares, with specific names and shareholding ratios disclosed [3]. - The top ten circulating shareholders also hold only ordinary shares, with their respective shareholding quantities and proportions provided [3][5]. Shareholder Details - The top shareholder is Beijing Fengyan Investment Management Co., Ltd. - Beijing Fengyan Ruiying No. 3 Private Securities Investment Fund, holding a significant number of shares [3]. - Other notable shareholders include China Industrial and Commercial Bank - China Europe Medical Health Mixed Securities Investment Fund and Huatai Securities Asset Management [3]. Documentation - The shareholder list is based on the records issued by China Securities Depository and Clearing Co., Ltd. [5].

Core Viewpoint - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, which is deemed compliant with the relevant regulations of the Major Asset Restructuring Management Measures for Listed Companies [1][2]. Group 1 - The restructuring meets the requirements of Article 11 of the Major Asset Restructuring Management Measures, ensuring that the asset valuation is fair and does not harm the legitimate rights and interests of the company and its shareholders [1]. - The company confirms that there are no legal obstacles to the transfer of assets prior to the transaction, and it does not involve the handling of related debts and liabilities [1]. - The company will maintain independence in personnel, assets, finance, institutions, and business after the restructuring, in accordance with the relevant regulations of the China Securities Regulatory Commission [1]. Group 2 - The restructuring complies with Article 43 of the Major Asset Restructuring Management Measures, ensuring that there are no ongoing investigations or violations of laws that could affect the transaction [2]. - The transaction is expected to enhance the quality of the company's assets and strengthen its ongoing operational capabilities without causing significant adverse changes to its financial status [2]. - The company will ensure that the transaction can be completed within the agreed timeframe, provided that all legal procedures and prerequisites are appropriately fulfilled [2]. Group 3 - The restructuring aligns with Article 44 of the Major Asset Restructuring Management Measures, promoting a diversified product matrix and preventing significant adverse impacts from competition or unfair related transactions [2].

Group 1 - The company plans to issue shares and pay cash to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. and raise supporting funds, which is referred to as "this transaction" [1] - To ensure fair information disclosure and protect investor interests, the company has applied for a stock suspension starting from May 22, 2025 [1] - The cumulative price change of the company's stock in the 20 trading days prior to the suspension was 12.27% after excluding the impact of the broader market index (399006.SZ) and 14.01% after excluding the impact of the industry index (801150.SL) [1] Group 2 - The stock price did not experience abnormal fluctuations, as the cumulative price change did not exceed 20% in the 20 trading days before the suspension [1]